J M

[J M @MarlowdvmM]

@TheMightyForego @Jim_Rothman Hey, Jack, thank you for your insight. It's so valuable, but can they really afford to wait that long? They are using SM102 in their melanoma vaccine, they're trying to get to market by the end of the year. They can't proceed without that license, correct? Thank you

[J M @MarlowdvmM]

@TheMightyForego They have kept us so in the dark. When it comes to the hepatitis b and ultimately a b- 101 3c cohort out comes. It's impossible for any of us to know what our shares are worth.

[J M @MarlowdvmM]

I'm sure you're getting tired of hearing from me Glenn, but you couldn't even hold the five dollar gain. After the momentum from moderna, maybe you should start talking about abus a little bit, I think that's what you're supposed to be doing. Since you're running abus
@gline

[J M @MarlowdvmM]

Jack could you please set the record straight.
@TheMightyForego

[J M @MarlowdvmM]

It's about time you put out a press release for q two.However, you still have not told us what happened with the three c https://t.co/rXsaQjpXAi a b 101, that's our money you're spending.We wanna know what you're doing with it!!! Our ceo works for roivant!!
@gline

[J M @MarlowdvmM]

@TheMightyForego @gortyaztec Honestly, I really don't know what the hell they're doing, https://t.co/EnGkrk9C2H looks like they've completely Shelved, the hepatitis b program won't talk to investors, so who knows.

[J M @MarlowdvmM]

@Roivant @gline @BioCentury Maybe he should catch up with the https://t.co/aLykCdgVK2 arbutus biopharma that he completely ignores.

[J M @MarlowdvmM]

@TheMightyForego So I take it from your response that this is gonna be a slow, drawn out process Now?

[J M @MarlowdvmM]

@TheMightyForego @Jim_Rothman So whats with the 2 week statement than?

[J M @MarlowdvmM]

@BiotechTV Maybe you can talk to somebody from arbutus biopharma. Looks like they've shelved our hepatitis b program and won't talk to shareholders anymore.

[J M @MarlowdvmM]

@TheMightyForego ?

[J M @MarlowdvmM]

@RNAiAnalyst What is your take on abus? Are we shelfing the hepatitis b program? Thx

[J M @MarlowdvmM]

Hello Matt, my name is Justin marlow dvm. I've been a shareholder of abus since July 2000. Over the years I have built a position of 110000 shares. I believe this is large enough to have a discussion with the investor relation team. It appears that team is not still there.

[J M @MarlowdvmM]

@BiotechCH Matt gline. Where are the results of the ab-101 1a/b cohort 3c 40 mg hbv? Study ended in February. Was a 28 day dosing?

[J M @MarlowdvmM]

Very glad to see some communication from arbutus today. Would love to see a 1 for 1 buyout of arbutus by roivant. Retire the same amount of the two companies shares. That way it will not dilute roivant shareholders.
@gline

[J M @MarlowdvmM]

@TheMightyForego @Jim_Rothman So you don't think this is due to a settlement?

[J M @MarlowdvmM]

@TheMightyForego So we have the best patent attorneys in the country. And we've been non aggressive to me that signals something, why would we do that Otherwise?

[J M @MarlowdvmM]

@Jim_Rothman @TheMightyForego I think one hundred percent were winding down.I'm just hoping that that's a carrot that they're waving in front of potential buyers to sweeten the pot

[J M @MarlowdvmM]

@TheMightyForego If this is correct with what you put from the thirty milligram, daddy for the chronicling infected, you don't need to go to the forty https://t.co/sOhUHj1dvS had a sixty eight to onehundred percent occupancy.

[J M @MarlowdvmM]

@TheMightyForego jack, I would really appreciate your insight as to what the hell you think is going on.,With the 40 mg Hbv chronically infected cohort for AB101 study. It was over in the end of February. They've seen the data and did not report it?